SCHEMBL23909450

SCHEMBL23909450

CCC(n1cnc2cnc3ccccc3c21)C1(O)CCCCC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP19 O94966 2/20 0.39
USP5 P45974 1/20 0.35
TSHR P16473 1/20 0.33
USP7 Q93009 1/20 0.33
SLC6A2 P23975 2/20 0.32
SLC6A4 P31645 1/20 0.32
AKT1 P31749 1/20 0.31
HRH3 Q9Y5N1 2/20 0.31
CHRM2 P08172 1/20 0.31
CHRM4 P08173 1/20 0.31
CHRM1 P11229 1/20 0.31
CHRM3 P20309 1/20 0.31
CDK1 P06493 1/20 0.31
CCNB1 P14635 1/20 0.31
TLR7 Q9NYK1 1/20 0.30
GCK P35557 1/20 0.30
PDE4A P27815 1/20 0.30
PDE4B Q07343 1/20 0.30
PDE4C Q08493 1/20 0.30
PDE4D Q08499 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23909449 1.00 USP19 (0.39) USP19USP5TSHRUSP7SLC6A2
SCHEMBL23909480 0.99 USP19 (0.37) USP19USP5TSHRUSP7SLC6A2
SCHEMBL23909478 0.99 USP19 (0.37) USP19USP5TSHRUSP7SLC6A2
SCHEMBL23909508 0.99 USP19 (0.37) USP19USP5TSHRUSP7SLC6A2
SCHEMBL23909504 0.87 USP5 (0.36) USP19USP5TSHRUSP7PDE4A
SCHEMBL23909503 0.87 USP5 (0.36) USP19USP5TSHRUSP7PDE4A
SCHEMBL23924908 0.87 MYC (0.33) USP19USP5TSHRUSP7CHRM2
SCHEMBL23924911 0.87 MYC (0.33) USP19USP5TSHRUSP7CHRM2
SCHEMBL23909466 0.83 USP5 (0.40) USP19USP5TSHRUSP7CDK1
SCHEMBL23909506 0.83 USP5 (0.40) USP19USP5TSHRUSP7CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12398134-B2 N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) 2025-08-26 US disclosed
US-20240140946-A1 N-1 BRANCHED CYCLOALKYL SUBSTITUTED IMIDAZO[4,5-c]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2024-05-02 US disclosed
US-11884662-B2 N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2024-01-30 US disclosed
EP-3802536-B1 N-1 BRANCHED CYCLOALKYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS 3M INNOVATIVE PROPERTIES CO (US) 2022-07-13 EP disclosed
US-20210317116-A1 N-1 BRANCHED CYCLOALKYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2021-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210317116-A1 N-1 BRANCHED CYCLOALKYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS IFNG, IFNAR1, CCL5 USP19 4375/4885USP5 3028/4885TSHR 2738/4885
US-11884662-B2 N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods IFNG, IFNAR1, CCL5 USP19 4375/4885USP5 3028/4885TSHR 2738/4885
US-12398134-B2 N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods IFNG, IFNAR1, CCL5 USP19 4686/4885USP5 3372/4885TSHR 2631/4885
US-20240140946-A1 N-1 BRANCHED CYCLOALKYL SUBSTITUTED IMIDAZO[4,5-c]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS IFNG, IFNAR1, CCL5 USP19 4686/4885USP5 3372/4885TSHR 2631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.